Search Results

TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announced the initiation of IND-enabling studies for TT-02332, a potent, selective and highly CNS-penetrating NLRP3 inflammasome inhibitor.

TransThera Sciences today announced that an oral presentation of tinengotinib clinical data in breast cancer was delivered at 2023 San Antonio Breast Cancer Symposium (SABCS) annual meeting.

TransThera Sciences, a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, announced the poster presentation at the 2024 American Association for Cancer Research to discuss the latest breaking research of tinengotinib for patients with advanced solid tumors harboring actionable FGFR1-3 alterations.

TransThera today announced that the randomized, controlled, global multicenter Phase 3 trial (FIRST-308) of tinengotinib versus physician’s choice to evaluate the efficacy and safety in subjects with FGFR-altered, chemotherapy- and FGFR Inhibitor-refractory/relapsed cholangiocarcinoma (CCA).

TransThera today announces the first patient has been dosed in the US for the Phase 3 trial FIRST-308 of tinengotinib (TT-00420).

TransThera Sciences (Nanjing) Inc. today announces to deliver two oral presentations of tinengotinib clinical data in cholangiocarcinoma (CCA) at 2023 European Society for Medical Oncology (ESMO) Congress, and in breast cancer at 2023 San Antonio Breast Cancer Symposium (SABCS) annual meeting respectively.

TransThera Sciences (Nanjing), Inc. (“TransThera”) announced that the U.S. Food and Drug Administration (“FDA”) approved the Investigational New Drug (“IND”) application of TT-01488, a non-covalent reversible Bruton’s Tyrosine Kinase (“BTK”) inhibitor, for the treatment of B-cell lymphomas on January 24, 2022, and TransThera will initiate the Phase I clinical trials in the U.S. soon.

TransThera Sciences announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its phase II stage product TT-00420 for the treatment of patients with Cholangiocarcinoma (CCA) who have no standard treatment options.